Critical Metals Corp. Merger with European Lithium Approved by European Lithium Securityholders

European Lithium shareholders and optionholders voted in favor of Critical Metals Corp.'s proposed acquisition at meetings held October 22, 2026, in Western Australia. The proposed transaction would give Critical Metals 100% of European Lithium's issued share capital and all its listed options through court-approved schemes of arrangement; the vote is an approval step, not confirmation that the acquisition has closed.

Analysis

The vote removes a material shareholder-approval hurdle, but it does not establish that the transaction will close or that it creates per-share value for Critical Metals Corp. The near-term setup is event-driven: a positive headline can support CRML, while the next meaningful confirmation is the court process and disclosure of any remaining conditions and timetable. A vote on the deal is not evidence of financing certainty, favorable consideration, or post-close execution capacity.

The key second-order issue is capital allocation. Combining exploration-stage businesses may improve strategic scale or portfolio breadth, but could also increase funding needs and dilute existing holders if consideration or subsequent project spending requires equity. The listed-option scheme adds another item to verify in the final capital structure; the article does not quantify its effect. European Lithium holders may benefit from transaction certainty, while CRML shareholders bear the risk that the acquisition expands the asset base faster than the company can fund development.

Over 1–3 months, court approval, closing conditions, consideration mechanics, and updated share-count/funding disclosures are the catalysts. Over 6–18 months, value depends on project-level progress and capital discipline, not the vote itself. Contrarian view: the approval is a procedural de-risking event, not a new operating-data point, so a sustained rerating without financing and execution evidence may be overdone. No valuation or deal-term data are supplied to support a directional target.

Key Decisions for Investors

• Do not chase CRML solely on the approval headline. Treat the vote as a modest reduction in transaction risk, not confirmation of accretion or a completed acquisition.
• Keep CRML on an event watchlist pending court outcome and company disclosure of remaining conditions, expected closing date, consideration, pro forma share count, and funding plan. These details are necessary before sizing a deal-driven position.
• If already long, assess exposure against the possibility of equity-funded consideration or incremental development spending; reduce the thesis if disclosures show material dilution without a credible funding and execution path.
• Falsifiers: a court or closing delay, a material change to transaction terms, or disclosures indicating substantially greater dilution or funding requirements would undermine the positive read. Court approval plus clear financing and credible project milestones would strengthen it.